1 to 2 hours:
time to peak plasma concentrations (Tmax)1
11 hours:
elimination half-life1
The clinical significance of these data is not known.
see qulipta
dosing options
INDICATION
QULIPTA® (atogepant) is indicated for the preventive treatment of migraine in adults.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
QULIPTA® (atogepant) is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.
WARNINGS AND PRECAUTIONS
Cases, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema, have been reported with use of QULIPTA. Hypersensitivity reactions can occur days after administration. If a hypersensitivity reaction occurs, discontinue QULIPTA and institute appropriate therapy.
ADVERSE REACTIONS
The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.
DRUG INTERACTIONS
Dose modifications are recommended when using the following:
- Episodic migraine: Strong CYP3A4 inhibitors; CYP3A4 inducers; or OATP inhibitors
- Chronic migraine: OATP inhibitors
In chronic migraine, avoid use with strong CYP3A4 inhibitors or with CYP3A4 inducers.
USE IN SPECIFIC POPULATIONS
Severe renal impairment or end-stage renal disease: In episodic migraine, 10 mg once daily. In chronic migraine, avoid use.
Avoid use in patients with severe hepatic impairment.
US-QLP-230210
IMPORTANT SAFETY INFORMATION
ADVERSE REACTIONS
The most common adverse reactions (≥5% and at least twice the rate of placebo) are nausea and constipation.
Please see full Prescribing Information.
Please see full Prescribing Information.